Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa open-label single-arm study of XH-S003 in primary IgA nephropathy
CTR20244548Phase 2Completed
- Sponsor
- Xinghao Pengbo
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of XH-S003 in IgA nephropathy (IgAN), sponsored by Xinghao Pengbo. Primary endpoint: Ratio of UPCR at Day 90 versus baseline. Started Dec 2024; status: completed.
02
Drugs
XH-S003
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20244548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244548.